Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: No association with clinical response to treatment or with disease relapse upon treatment discontinuation

Arthritis Research and Therapy

Volumn 16, Issue 4, 2014, Pages

  Paramarta, Jacqueline E ^a   Baeten, Dominique L ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DRUG ANTIBODY; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALAZOSULFAPYRIDINE; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; PERIPHERAL SPONDYLOARTHRITIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SKIN MANIFESTATION; SPONDYLARTHRITIS; TOPICAL TREATMENT; TREATMENT OUTCOME; TREATMENT RESPONSE; BLOOD; FEMALE; IMMUNOLOGY; MALE; MIDDLE AGED; RECURRENT DISEASE; SPONDYLITIS, ANKYLOSING;

ADALIMUMAB; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECURRENCE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME;

EID: 84904772791     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4675     Document Type: Article

References (34)

1. Van den Bosch F, Kruithof E, Baeten D, Herssens A, De Keyser F, Mielants H, Veys EM. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy. Arthritis Rheum 2002, 46:755-765. 10.1002/art.511, 11920412.
2. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnica-Ihle E, Kellner H, Krause A, Schneider M, So¨rensen H, Zeidler H, Thriene W, Sieper J. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002, 359:1187-1193. 10.1016/S0140-6736(02)08215-6, 11955536.
3. Antoni C, Krueger GG, de Vlam K, Birbara C, Beutler A, Guzzo C, Zhou B, Dooley LT, Kavanaugh A, for the IMPACT 2 investigators Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150-1157. 10.1136/ard.2004.032268, 1755609, 15677701, for the IMPACT 2 investigators.
4. Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, Arora V, Pangan AL. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013, 72:815-822. 10.1136/annrheumdis-2012-201766, 3664374, 22772328.
5. Paramarta JE, De Rycke L, Heijda TF, Ambarus CA, Vos K, Dinant HJ, Tak PP, Baeten DL. Efficacy and safety of adalimumab for the treatment of peripheral arthritis in spondyloarthritis patients without ankylosing spondylitis or psoriatic arthritis. Ann Rheum Dis 2013, 72:1793-1799. 10.1136/annrheumdis-2012-202245, 23139265.
6. Van der Laken CJ, Voskuyl AE, Roos JC, Stigter Van Walsum M, de Groot ER, Wolbink G, Dijkmans BA, Aarden LA. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007, 66:253-256. 1798492, 16793840.
7. van Schouwenburg PA, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot E, Hart M, van Ham SM, Rispens T, Aarden L, Wolbink GJ, Wouters D. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013, 72:104-109. 10.1136/annrheumdis-2012-201445, 22759910.
8. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013, 72:165-178. 10.1136/annrheumdis-2012-202545, 23178294.
9. Garceˆs S, Demengeot J, Benito-Garcia E. The immunogenicity of anti-TNF therapy in immune-mediated inflammatory diseases: a systematic review of the literature with a meta-analysis. Ann Rheum Dis 2013, 72:1947-1955. 10.1136/annrheumdis-2012-202220, 23223420.
10. Arends S, Lebbink HR, Spoorenberg A, Bungener LB, Roozendaal C, van der Veer E, Houtman PM, Griep EN, Limburg PC, Kallenberg CG, Wolbink GJ, Brouwer E. The formation of autoantibodies and antibodies to TNF-α blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 2010, 28:661-668.
11. de Vries MK, Wolbink GJ, Stapel SO, de Groot ER, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007, 66:133-134. 1798422, 17178760.
12. de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007, 66:1252-1254. 10.1136/ard.2007.072397, 1955152, 17472991.
13. Ducourau E, Mulleman D, Paintaud G, Miow Lin DC, Laufe´ron F, Ternant D, Watier H, Goupille P. Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases. Arthritis Res Ther 2011, 13:R105. 10.1186/ar3386, 3218920, 21708018.
14. Plasencia C, Pascual-Salcedo D, Nuño L, Bonilla G, Villalba A, Peiteado D, Di´ez J, Nagore D, del Agua AR, Moral R, Martin-Mola E, Balsa A. Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012, 71:1955-1960. 10.1136/annrheumdis-2011-200828, 22563028.
15. van Kuijk AW, de Groot M, Stapel SO, Dijkmans BA, Wolbink GJ, Tak PP. Relationship between the clinical response to adalimumab treatment and serum levels of adalimumab and anti-adalimumab antibodies in patients with psoriatic arthritis. Ann Rheum Dis 2010, 69:624-625. 10.1136/ard.2009.108787, 20223840.
16. de Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, Nurmohamed MT, Dijkmans BA, Aarden LA, Wolbink GJ. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009, 68:1787-1788. 10.1136/ard.2009.109702, 19822712.
17. Baraliakos X, Listing J, Rudwaleit M, Brandt J, Alten R, Burmester G, Gromnica-Ihle E, Haibel H, Schewe S, Schneider M, So¨rensen H, Zeidler H, Visvanathan S, Sieper J, Braun J. Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis. J Rheumatol 2007, 34:510-515.
18. Krzysiek R, Breban M, Ravaud P, Prejean MV, Wijdenes J, Roy C, Henry YD, Barbey C, Trappe G, Dougados M, Emilie D, French Ankylosing Spondylitis Infliximab Network Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 2009, 61:569-576. 10.1002/art.24275, 19405015, French Ankylosing Spondylitis Infliximab Network.
19. de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT, Aarden LA, Stapel SO, Peters MJ, van Denderen JC, Dijkmans BA, Wolbink GJ. Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 2009, 68:531-535. 10.1136/ard.2008.089979, 18375542.
20. Inman RD, Davis JC, Heijde D, Diekman L, Sieper J, Kim SI, Mack M, Han J, Visvanathan S, Xu Z, Hsu B, Beutler A, Braun J. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008, 58:3402-3412. 10.1002/art.23969, 18975305.
21. Kavanaugh A, McInnes I, Mease P, Krueger GG, Gladman D, Gomez-Reino J, Papp K, Zrubek J, Mudivarthy S, Mack M, Visvanathan S, Beutler A. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009, 60:976-986. A published erratum appears in Arthritis Rheum 2010, 62:2555, 10.1002/art.24403, 19333944.
22. Maneiro JR, Salgado E, Gomez-Reino JJ. Immunogenicity of monoclonal antibodies against tumor necrosis factor used in chronic immune-mediated inflammatory conditions: systematic review and meta-analysis. JAMA Intern Med 2013, 173:1416-1428. 10.1001/jamainternmed.2013.7430, 23797343.
23. Glintborg B, Ostergaard M, Krogh NS, Andersen MD, Tarp U, Loft AG, Lindegaard HM, Holland-Fischer M, Nordin H, Jensen DV, Olsen CH, Hetland ML. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry. Arthritis Rheum 2013, 65:1213-1223. 10.1002/art.37876, 23460467.
24. Glintborg B, Ostergaard M, Krogh NS, Dreyer L, Kristensen HL, Hetland ML. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010, 69:2002-2008. 10.1136/ard.2009.124446, 20511613.
25. van Schouwenburg PA, Bartelds GM, Hart MH, Aarden L, Wolbink GJ, Wouters D. A novel method for the detection of antibodies to adalimumab in the presence of drug reveals hidden immunogenicity in rheumatoid arthritis patients. J Immunol Methods 2010, 362:82-88. 10.1016/j.jim.2010.09.005, 20833178.
26. Dougados M, van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, Cats A, Dijkmans B, Olivieri I, Pasero G, Veys E, Zeidler H. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 34:1218-1227. 10.1002/art.1780341003, 1930310.
27. Amor B, Dougados M, Mijiyawa M. [Criteria of the classification of spondylarthropathies] [in French]. Rev Rhum Mal Osteoartic 1990, 57:85-89.
28. Machado P, Landewe´ R, Lie E, Kvien TK, Braun J, Baker D, van der Heijde D, for the Assessment of SpondyloArthritis International Society Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 2011, 70:47-53. 10.1136/ard.2010.138594, 21068095, for the Assessment of SpondyloArthritis International Society.
29. Paramarta JE, Heijda TF, Baeten DL. Fast relapse upon discontinuation of tumour necrosis factor blocking therapy in patients with peripheral spondyloarthritis. Ann Rheum Dis 2013, 72:1581-1582. 10.1136/annrheumdis-2013-203327, 23661496.
30. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468. 10.1001/jama.2011.406, 21486979.
31. Jani M, Barton A, Warren RB, Griffiths CE, Chinoy H. The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology (Oxford) 2014, 53:213-222. 10.1093/rheumatology/ket260, 3894670, 23946436.
32. Fagerli KM, Lie E, van der Heijde D, Heiberg MS, Lexberg AS, Rødevand E, Kalstad S, Mikkelsen K, Kvien TK. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study. Ann Rheum Dis 2014, 73:132-137. 10.1136/annrheumdis-2012-202347, 23291385.
33. Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004, 2:542-553. 10.1016/S1542-3565(04)00238-1, 15224278.
34. Me´ric JC, Mulleman D, Ducourau E, Laufe´ron F, Miow Lin DC, Watier H, Goupille P, Paintaud G. Therapeutic drug monitoring of infliximab in spondyloarthritis: an observational open-label study. Ther Drug Monit 2011, 33:411-416. 10.1097/FTD.0b013e318224f83d, 21743380.